Łukasiewicz Research Network - Industrial Chemistry Institute named after Prof. Ignacy Mościcki

The medicinal product is intended for the treatment of hematopoietic malignancies: hairy cell leukemia (at all stages), chronic lymphocytic leukemia, and low-grade non-Hodgkin lymphomas that are resistant to other drugs.

Dosage form: solution for infusion

ATC: L01BB04